MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Rapid Onset Action of Salbutamol Versus Formoterol

Phase 4
Conditions
Bronchial Asthma
Interventions
First Posted Date
2009-05-13
Last Posted Date
2009-05-13
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Target Recruit Count
78
Registration Number
NCT00900874
Locations
🇮🇳

AIIMS, New Delhi, India

Role of Airway Hyperresponsiveness on Performance in Elite Swimmers.

Not Applicable
Completed
Conditions
Asthma
Interventions
First Posted Date
2009-04-06
Last Posted Date
2013-05-13
Lead Sponsor
Laval University
Target Recruit Count
57
Registration Number
NCT00876135
Locations
🇨🇦

Institut Universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec, Canada

Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: beclometasone /formoterol
Drug: Ventolin
First Posted Date
2009-03-16
Last Posted Date
2017-03-30
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
2079
Registration Number
NCT00861926
Locations
🇮🇹

Pr Papi, Ferrara, Italy

Symbicort Onset of Action 2

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: budesonide/formoterol
Drug: fluticasone/salmeterol
Drug: albuterol
First Posted Date
2008-03-28
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Target Recruit Count
48
Registration Number
NCT00646009

Rapid Diagnosis of Pulmonary Tuberculosis

Not Applicable
Conditions
Tuberculosis
Interventions
First Posted Date
2008-02-06
Last Posted Date
2012-07-24
Lead Sponsor
University of Cape Town
Target Recruit Count
600
Registration Number
NCT00608790
Locations
🇿🇦

University of Cape Town, Cape Town, South Africa

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

First Posted Date
2008-01-08
Last Posted Date
2016-01-21
Lead Sponsor
Northwell Health
Target Recruit Count
95
Registration Number
NCT00588406
Locations
🇺🇸

Nassau University Medical Center, East Meadow, New York, United States

🇺🇸

Long Island Jewish Medical Center, Queens, New York, United States

🇺🇸

Jacobi Medical Center, Bronx, New York, United States

Albuterol HFA MDI in Pediatric Participants With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2007-12-20
Last Posted Date
2021-11-12
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
103
Registration Number
NCT00577655
Locations
🇺🇸

Asthma & Allergy Associates, PC, Elmira, New York, United States

🇺🇸

Virginia Adult & Pediatric Allergy & Asthma, Richmond, Virginia, United States

🇺🇸

Pediatric Care Medical Group, Inc., Huntington Beach, California, United States

and more 10 locations

Optimising the Propranolol Block Model

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2007-10-25
Last Posted Date
2017-08-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
18
Registration Number
NCT00549120
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms

Phase 3
Completed
Conditions
Bronchial Asthma
Interventions
Drug: Beclomethasone dipropionate/Salbutamol combination
Drug: Salbutamol
Drug: Beclomethasone dipropionate
First Posted Date
2007-07-06
Last Posted Date
2020-08-03
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
283
Registration Number
NCT00497523
Locations
🇵🇱

Zaklad Alergologii Dzieciecej, Bialystok, Poland

🇵🇱

Wojskovy Szpital Klinikzny, Krakow, Poland

🇵🇱

Priwtny Gabinet Pediatriczno - Alergologiczny, Rabka Zdroj, Poland

and more 16 locations

Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2007-06-19
Last Posted Date
2010-04-13
Lead Sponsor
Medical University of Lodz
Target Recruit Count
96
Registration Number
NCT00487773
Locations
🇵🇱

Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland

© Copyright 2025. All Rights Reserved by MedPath